Deucravacitinib Impurity7 NEW

Deucravacitinib Impurity7;2417138-48-6

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

Product Information

• Product Code：D084007

• English Name：Deucravacitinib Impurity 7

• English Alias：6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

• CAS No.：2417138-48-6

• Molecular Formula：C₁₆H₁₅D₃N₈O₂

• Molecular Weight：357.39

Advantages

• High-Purity Isotopic Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C, DEPT), HRMS (isotope peak analysis), and elemental analysis, with ≥99.5% deuterium labeling (methyl-d3), providing an accurate isotopic internal standard for Deucravacitinib impurity analysis.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.1% in methanol-water (1:1) mixture within 6 months, ensuring no deuterium loss for long-term bioanalytical use.

Applications

• Quantitative Calibration：Used as a deuterated internal standard in UPLC-MS/MS to correct matrix effects, improving impurity quantification precision (RSD <2%) in Deucravacitinib API and formulations, meeting FDA requirements for genotoxic impurity testing.

• Metabolic Kinetic Study：Tracks metabolic pathways (e.g., deamination, methoxy oxidation) via deuterium tracing, providing data for toxicological evaluation of process impurities.

• Method Validation：Verifies UPLC resolution (≥2.8) and mass spectral isotopic response linearity (0.01-10 ng/mL) during method development, ensuring LOD reaches 0.003 ng/mL.

Background Description

Research Status

• Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 7 minutes, baselining deuterated (m/z +3 Da) and non-deuterated impurities, with LOD of 0.001 ng/mL.

• Formation Mechanism：Formed by reductive amination of 4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3,6-dione with deuterated methylamine (ND3·DCl) under reducing agents (e.g., sodium borohydride); optimizing reaction temperature (50-60℃) and deuterated reagent dosage inhibits byproduct formation.

• Safety Evaluation：In vitro cytotoxicity shows IC₅₀ of 197.6 μM against HaCaT cells (Deucravacitinib IC₅₀=6.5 μM), with lower toxicity than the drug. Deuteration does not significantly alter metabolism, but long-term stability testing (60℃/90%RH) monitors amino oxidation risks.

NOTE！

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!